真性红细胞增多症与原发性血小板增多症的白血病转化:基因组特征预测转化时间
该研究对49例PV和ET白血病转化样本进行靶向二代测序,以分层分类识别出3个与转化时间相关的分子组。短期转化多表现为复杂分子格局及IDH1/2、RUNX1、U2AF1突变,长期转化与TP53、NRAS、BCORL1突变相关。部分突变在慢性期已存在,而其他突变在转化前1年仍未检出,提示转化由时间依赖性分子机制驱动。
要点
- PV/ET白血病转化罕见但预后差,转化间隔从数年至>20年不等。
- 短期转化多伴复杂分子格局及IDH1/2、RUNX1、U2AF1突变。
- 长期转化与TP53、NRAS、BCORL1突变相关,部分慢性期已存在。
核心结论
- PV和ET的白血病转化可能由不同的时间依赖性分子机制驱动。
- 基因组特征可预测PV和ET白血病转化的时间。
研究设计与样本
- 对49例PV和ET白血病转化样本进行靶向二代测序的分子评估。
- 采用分层分类方法分析分子特征与转化时间的关系。
主要发现
- 识别出3个与不同转化时间相关的分子组。
- 短期转化多表现为复杂分子格局及IDH1/2、RUNX1、U2AF1突变。
- 长期转化与TP53、NRAS、BCORL1突变相关。
- 部分突变在慢性期已存在,短期转化者等位基因负荷显著,长期转化者(尤其TP53突变)等位基因负荷极低。
- 其他突变在白血病转化前1年仍未检出。
临床怎么用
- 对PV和ET患者可考虑靶向测序检测IDH1/2、RUNX1、U2AF1、TP53、NRAS、BCORL1等基因突变。
- 根据突变谱和等位基因负荷评估白血病转化风险及可能的时间窗。
局限性
- 样本量较小(49例转化样本)。
- 为回顾性分子评估,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis and leukemic evolution is highly variable, from a few years to >20 years. We performed a molecular evaluation of 49 leukemic transformations of PV and ET by targeted next-generation sequencing. Using a hierarchical classification, we identified 3 molecular groups associated with a distinct time to leukemic transformation. Short-term transformations were mostly characterized by a complex molecular landscape and mutations in IDH1/2, RUNX1, and U2AF1 genes, whereas long-term transformations were associated with mutations in TP53, NRAS, and BCORL1 genes. Studying paired samples from chronic phase and transformation, we detected some mutations already present during the chronic phase, either with a significant allele burden (short-term transformation) or with a very low allele burden (especially TP53 mutations). However, other mutations were not detected even 1 year before leukemic transformation. Our results suggest that the leukemic transformation of PV and ET may be driven by distinct time-dependent molecular mechanisms.
引用
- Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020. PMID: 33035330. doi:10.1182/bloodadvances.2020002271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。